Trichoscopic Features of Scalp Discoid Lupus Erythematosus versus Lichen Planopilaris: A Systematic Review
CONCLUSION: This article provides a comprehensive review of the literature and delineates the trichoscopic differences and peculiarities of scalp DLE and LPP, including the correlation of dermoscopic features with histopathological findings.PMID:38616887 | PMC:PMC11015838 | DOI:10.2147/CCID.S460742 (Source: Clinical, Cosmetic and Investigational Dermatology)
Source: Clinical, Cosmetic and Investigational Dermatology - April 15, 2024 Category: Dermatology Authors: Shreya K Gowda Enzo Errichetti Vishal Thakur Maitreyee Panda Siddhartha Dash Akash Agarwal Madhusmita Sethy Pavithra Ayyanar Biswanath Behera Source Type: research

Ocular lichen planus as a cause of recurrent restrictive strabismus
(Source: Journal of AAPOS)
Source: Journal of AAPOS - April 15, 2024 Category: Opthalmology Authors: Leyla Yavuz Saricay, Hajirah Saeed, Michael Yoon, Anna M. Stagner, Lindsey A. MacFarlane, Eric D. Gaier, Jia Yin, David G. Hunter Tags: Short Report Source Type: research

Antitubercular drug-induced lichen planus: A case study with a mini literature review
CONCLUSION: Lichenoid drug eruptions are characterized by type IV hypersensitivity reactions, and rechallenge is required to ensure safer treatment since the risk of disseminated and multi-drug-resistant tuberculosis increases with the cessation of antitubercular therapy.PMID:38605770 | PMC:PMC11006073 | DOI:10.4103/jfmpc.jfmpc_499_23 (Source: Primary Care)
Source: Primary Care - April 12, 2024 Category: Primary Care Authors: Sanjana C Shanmukhappa Winny John Vineeta Kevalramani Srivatsa Lokeshwaran Shireen Furtado Mahesh Nosenoor Source Type: research

Antitubercular drug-induced lichen planus: A case study with a mini literature review
CONCLUSION: Lichenoid drug eruptions are characterized by type IV hypersensitivity reactions, and rechallenge is required to ensure safer treatment since the risk of disseminated and multi-drug-resistant tuberculosis increases with the cessation of antitubercular therapy.PMID:38605770 | PMC:PMC11006073 | DOI:10.4103/jfmpc.jfmpc_499_23 (Source: Primary Care)
Source: Primary Care - April 12, 2024 Category: Primary Care Authors: Sanjana C Shanmukhappa Winny John Vineeta Kevalramani Srivatsa Lokeshwaran Shireen Furtado Mahesh Nosenoor Source Type: research

Antitubercular drug-induced lichen planus: A case study with a mini literature review
CONCLUSION: Lichenoid drug eruptions are characterized by type IV hypersensitivity reactions, and rechallenge is required to ensure safer treatment since the risk of disseminated and multi-drug-resistant tuberculosis increases with the cessation of antitubercular therapy.PMID:38605770 | PMC:PMC11006073 | DOI:10.4103/jfmpc.jfmpc_499_23 (Source: Primary Care)
Source: Primary Care - April 12, 2024 Category: Primary Care Authors: Sanjana C Shanmukhappa Winny John Vineeta Kevalramani Srivatsa Lokeshwaran Shireen Furtado Mahesh Nosenoor Source Type: research

Histologic and Histomorphometric Comparative Study of Oral Lichen Planus Versus Oral Lichenoid Reaction
CONCLUSION: We showed a significant difference in the nuclear and cellular area, nuclear-to-cytoplasm ratio between OLPs and OLRs, and healthy controls, but there was no statistically significant difference between OLPs and OLRs. Thus, these parameters cannot be applied to differentiate diagnoses between OLPs and OLRs.PMID:38566645 | PMC:PMC10982157 | DOI:10.1007/s12070-023-04411-y (Source: Cancer Control)
Source: Cancer Control - April 3, 2024 Category: Cancer & Oncology Authors: Narges Ghazi Nasrollah Saghravanian Majid Mirhashemi Hamidreza Shahabi Source Type: research

Lichen Planus and Lichen Planus Pigmentosus Inversus Following COVID-19 Vaccine in Dark Phototype Patients
Actas Dermosifiliogr. 2024 Apr 1:S0001-7310(24)00281-3. doi: 10.1016/j.ad.2024.03.030. Online ahead of print.NO ABSTRACTPMID:38570089 | DOI:10.1016/j.ad.2024.03.030 (Source: Actas Dermo-Sifiliograficas)
Source: Actas Dermo-Sifiliograficas - April 3, 2024 Category: Dermatology Authors: S R Gil-Qui ñones J A Velandia F Velandia M Y Barrera Source Type: research

Lichen Planus and Lichen Planus Pigmentosus Inversus Following COVID-19 Vaccine in Dark Phototype Patients
Actas Dermosifiliogr. 2024 Apr 1:S0001-7310(24)00281-3. doi: 10.1016/j.ad.2024.03.030. Online ahead of print.NO ABSTRACTPMID:38570089 | DOI:10.1016/j.ad.2024.03.030 (Source: Actas Dermo-Sifiliograficas)
Source: Actas Dermo-Sifiliograficas - April 3, 2024 Category: Dermatology Authors: S R Gil-Qui ñones J A Velandia F Velandia M Y Barrera Source Type: research

Lichen Planus and Lichen Planus Pigmentosus Inversus Following COVID-19 Vaccine in Dark Phototype Patients
Actas Dermosifiliogr. 2024 Apr 1:S0001-7310(24)00281-3. doi: 10.1016/j.ad.2024.03.030. Online ahead of print.NO ABSTRACTPMID:38570089 | DOI:10.1016/j.ad.2024.03.030 (Source: Actas Dermo-Sifiliograficas)
Source: Actas Dermo-Sifiliograficas - April 3, 2024 Category: Dermatology Authors: S R Gil-Qui ñones J A Velandia F Velandia M Y Barrera Source Type: research

Lichen Planus and Lichen Planus Pigmentosus Inversus Following COVID-19 Vaccine in Dark Phototype Patients
Actas Dermosifiliogr. 2024 Apr 1:S0001-7310(24)00281-3. doi: 10.1016/j.ad.2024.03.030. Online ahead of print.NO ABSTRACTPMID:38570089 | DOI:10.1016/j.ad.2024.03.030 (Source: Actas Dermo-Sifiliograficas)
Source: Actas Dermo-Sifiliograficas - April 3, 2024 Category: Dermatology Authors: S R Gil-Qui ñones J A Velandia F Velandia M Y Barrera Source Type: research

Oral Lichen Planus Successfully Treated With Upadacitinib
J Drugs Dermatol. 2024 Apr 1;23(4):e104-e106. doi: 10.36849/JDD.7859.ABSTRACTWith the rise of Janus kinase (JAK) and Signal Transducer and Activator of Transcription (STAT) inhibitor use in dermatologic conditions, there has been increasing hope in treating extensive and difficult-to-treat inflammatory cutaneous conditions. Today we report a case of oral lichen planus successfully treated with an oral JAK1 inhibitor, upadacitinib. This case had been unresponsive by several standard methods but responded with 70% improvement within 1 month when treated with upadacitinib.  J Drugs Dermatol. 2024;23(4):7859.&nbsp...
Source: Journal of Drugs in Dermatology - April 2, 2024 Category: Dermatology Authors: Kristin Slater Katelyn Halash Francisca Kartono Source Type: research